Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AegirBio AB (SUBGEN) Stock Price & Analysis

SUBGEN Stock Chart & Stats

SEK 0.03SEK 0.00(6.67%)
At close: 5:30 PM GMT+1
SEK 0.03SEK 0.04SEK 0.053 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
SEK 0.03 - SEK 0.03
52-Week Range
SEK 0.03 - SEK 19.68
Previous Close
SEK 0.03
Volume
N/A
Average Volume (3M)
16.20M
Market Cap
SEK 72.42M
Enterprise Value
SEK 380.03M
Total Cash (Recent Filing)
SEK 19.51M
Total Debt (Recent Filing)
SEK 240.41M
Price to Earnings (P/E)
―
Beta
5.58
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The 90.7% TTM revenue increase indicates stronger commercial traction and expanding business scale. If this growth persists, it can improve operating leverage, support investment in the diagnostics portfolio, and provide a foundation for eventual margin recovery.

Operating Cash Flow

The shift to positive operating cash flow is a constructive improvement in the company’s underlying cash conversion. Sustained operating inflows would reduce reliance on external financing and give management greater flexibility to support commercialization and product development.

Current Capitalization

Positive equity and moderate TTM leverage provide a more stable capital base than the company’s earlier periods of negative equity. This supports continued operations and leaves some financial capacity for growth, provided losses and borrowing do not continue worsening.

Bears Say

Severe Unprofitability

Very large operating and net losses show that revenue growth is not yet translating into economically sustainable earnings. Persistently high costs relative to sales can consume capital, limit strategic flexibility, and make profitability dependent on substantial operating improvement.

Negative Free Cash Flow

Negative free cash flow means the company is not yet generating enough cash after its investment needs to fund itself sustainably. Continued shortfalls could require additional financing, constrain product and commercial investment, and increase vulnerability if losses persist.

Rising Leverage

The sharp increase in debt materially raises financial risk while the company remains loss-making and generates negative free cash flow. Historical negative equity and current negative returns further indicate that additional borrowing could increase dilution or repayment pressure.

SUBGEN FAQ

What was AegirBio AB’s price range in the past 12 months?
AegirBio AB lowest stock price was kr 0.03 and its highest was kr 19.68 in the past 12 months.
What is AegirBio AB’s market cap?
AegirBio AB’s market cap is kr 72.42M.
When is AegirBio AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AegirBio AB’s earnings last quarter?
AegirBio AB released its earnings results on Aug 20, 2026. The company reported -kr 0.015 earnings per share for the quarter.
Is AegirBio AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does AegirBio AB pay dividends?
AegirBio AB does not currently pay dividends.
What is AegirBio AB’s EPS estimate?
AegirBio AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AegirBio AB have?
AegirBio AB has 1,736,062,300 shares outstanding.
What happened to AegirBio AB’s price movement after its last earnings report?
AegirBio AB reported an EPS of -kr 0.015 in its last earnings report. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of AegirBio AB?
Currently, no hedge funds are holding shares in SE:SUBGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology